NCT02717988View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Rheumatoid Arthritis

Interventions

DRUG

SKI-O-703 capsule

SKI-O-703 25 mg capsule or 200 mg capsule without excipient

DRUG

Placebo capsule

Placebo 180 mg capsule filled with microcrystalline cellulose

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors

Lead Sponsor

Collaborators (1)

PPD Development, LP

All Listed Sponsors

collaborator

PPD Development, LP

INDUSTRY

lead

Oscotec Inc.

INDUSTRY